Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
9
|
| pubmed:dateCreated |
1992-1-13
|
| pubmed:abstractText |
In a non-randomized study the treatment results of 59 patients with disseminated seminoma were evaluated: 21 patients were treated with a VAB-6 combination and 38 with a CP (cyclophosphamide and cisplatin) combination. After VAB-6 CR was observed in 8 patients and 6 achieved CR with additional treatment: 1 with chemotherapy (PVB) and 5 with radiotherapy (RT). The final CR rate was 67%. At a median follow-up of 38 (11-70) months 15 (71%) are alive, and 11 of them (52%) are NED; 6 have died. Of the 38 patients treated with CP alone only 18 achieved CR and 9 had a CR after additional RT and 1 chemotherapy (VAB-6), the overall CR rate was 72%. The median follow-up is 24 (4-55) months, 28 (74%) are alive, 24 (66%) are currently NED, and 9 have died. Both regimens were well tolerated, the main toxicity being leukopenia: 48% (WHO grade 111-1V-5%) for VAB-6, and 59% (13%) for CP. Hearing loss was registered in 8 patients receiving CP and in 2 receiving VAB-6. There were no fatal toxicities. Thus, VAB-6 and CP regimens seem to have compatible and high activity in disseminated seminoma.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Bleomycin,
http://linkedlifedata.com/resource/pubmed/chemical/Cisplatin,
http://linkedlifedata.com/resource/pubmed/chemical/Cyclophosphamide,
http://linkedlifedata.com/resource/pubmed/chemical/Dactinomycin,
http://linkedlifedata.com/resource/pubmed/chemical/Vinblastine
|
| pubmed:status |
MEDLINE
|
| pubmed:month |
Oct
|
| pubmed:issn |
0923-7534
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
2
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
667-72
|
| pubmed:dateRevised |
2006-11-15
|
| pubmed:meshHeading |
pubmed-meshheading:1720656-Adolescent,
pubmed-meshheading:1720656-Adult,
pubmed-meshheading:1720656-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:1720656-Bleomycin,
pubmed-meshheading:1720656-Chi-Square Distribution,
pubmed-meshheading:1720656-Cisplatin,
pubmed-meshheading:1720656-Cyclophosphamide,
pubmed-meshheading:1720656-Dactinomycin,
pubmed-meshheading:1720656-Dysgerminoma,
pubmed-meshheading:1720656-Follow-Up Studies,
pubmed-meshheading:1720656-Humans,
pubmed-meshheading:1720656-Male,
pubmed-meshheading:1720656-Middle Aged,
pubmed-meshheading:1720656-Neoplasm Metastasis,
pubmed-meshheading:1720656-Prognosis,
pubmed-meshheading:1720656-Remission Induction,
pubmed-meshheading:1720656-Survival Rate,
pubmed-meshheading:1720656-Testicular Neoplasms,
pubmed-meshheading:1720656-USSR,
pubmed-meshheading:1720656-Vinblastine
|
| pubmed:year |
1991
|
| pubmed:articleTitle |
VAB-6 and cisplatin-cyclophosphamide combinations in the treatment of metastatic seminoma patients: the U.S.S.R. experience.
|
| pubmed:affiliation |
Clinical Pharmacology Department, All-Union Cancer Research Center AMS of the U.S.S.R., Moscow.
|
| pubmed:publicationType |
Journal Article,
Comparative Study
|